pharmaphorum February 13, 2022
German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.
Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity.
Merck will put BioAI through its paces as a way to identify if new drug candidates pose a risk of liver toxicity, focusing on compounds with known issues that regular preclinical testing was unable to identify.
If all goes to plan, Merck has the option to obtain up...
Today's Sponsors
Today's Sponsor